Combination biologic therapy for ankylosing spondylitis
Treatments studied
Part of Bones, joints & muscles clinical trials.
This trial tests whether combining two biologic medications (adalimumab and secukinumab) can better relieve symptoms of ankylosing spondylitis, a type of arthritis that affects the spine. It may help if you have not responded well to standard nonsteroidal anti-inflammatory drugs (NSAIDs) and you have active disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with ankylosing spondylitis.
- You have tried at least two NSAIDs (like ibuprofen or naproxen) for a total of 4 weeks or more, but they didn't work well enough, or you cannot take them due to side effects or health reasons.
- You have moderate to severe disease activity, as shown by a BASDAI score of 4 or more and a back pain score of 4 or more.
- You are willing to take two biologic medications: adalimumab and secukinumab.
- If you are a woman of childbearing age, you agree to use effective birth control during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
This trial tests a new oral medication called LNK01001 for adults with active ankylosing spondylitis. It aims to reduce pain, stiffness, and inflammation when standard NSAID treatments no longer help.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
This trial tests whether a single infusion of stem cells from a healthy donor's bone marrow can help reduce inflammation and pain in people with active ankylosing spondylitis. If you are young and have not been helped by standard treatments, this study might offer a new option.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
This study looks at treatments for people with ankylosing spondylitis, a type of arthritis that affects the spine. It aims to find better ways to manage symptoms and improve quality of life.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.